ArQule Inc. (ARQL)
-NasdaqGM 2.73 
0.02(0.73%) 3:51PM EDT - Nasdaq Real Time Price
| Prev Close: | 2.75 |
|---|
| Open: | 2.73 |
|---|
| Bid: | 2.73 x 22200 |
|---|
| Ask: | 2.74 x 2900 |
|---|
| 1y Target Est: | 4.54 |
|---|
| Beta: | 1.08 |
|---|
| Next Earnings Date: | 1-Aug-13 |
|---|
| Day's Range: | 2.71 - 2.77 |
|---|
| 52wk Range: | 1.98 - 6.98 |
|---|
| Volume: | 111,076 |
|---|
| Avg Vol (3m): | 327,433 |
|---|
| Market Cap: | 170.96M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.20 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- ARQULE INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Financial Statements and ExhibitsEDGAR Online(Thu, May 23)
- ARQULE INC FinancialsEDGAR Online Financials(Tue, May 14)
- Earnings Volatility Drives These Healthcare Stocks in a New Directionat Wall St. Cheat Sheet(Sun, May 12)
- Narrower-than-Expected Loss at ArQuleZacks(Thu, May 9)
- ArQule Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, May 8)
- ArQule Earnings: Everything You Must Know Nowat Wall St. Cheat Sheet(Wed, May 8)
- Q1 2013 ArQule, Inc. Earnings Release - 07:00 am ETCCBN(Wed, May 8)
- ArQule Reports First Quarter 2013 Financial ResultsBusiness Wire(Wed, May 8)
- ARQULE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Wed, May 8)
- ArQule to Report First Quarter 2013 Financial Results on May 8, 2013Business Wire(Wed, May 1)
- ArQule, Inc. to Present at Needham 12th Annual Healthcare ConferenceBusiness Wire(Tue, Apr 23)
- Early-Stage Clinical Data Highlights From AACR 2013at Seeking Alpha(Wed, Apr 17)
- Data on ArQule's ARQ 092Zacks(Wed, Apr 10)
- ArQule’s Novel AKT Pathway Inhibitor, ARQ 092, Demonstrates Safety, Target Inhibition in Phase 1 TrialBusiness Wire(Tue, Apr 9)
- ArQule Regains ARQ 092 RightsZacks(Tue, Apr 2)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 5.13 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.46 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.12 |
|---|
| Mean Recommendation*: | 2.3 |
|---|
| PEG Ratio (5 yr expected): | -1.20 |
|---|
Business Summary
ArQule, Inc., a clinical-stage biotechnology company, engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes.
View More